Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Endovascular treatment for cerebral venous sinus thrombosis - a single center study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Expression of ET(A) and ET(B) receptor mRNA in human cerebral arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intracerebral hæmoragi tolv dage efter vaccination med ChAdOx1 nCoV-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. SARS-CoV-2-vaccineinduceret immuntrombose og trombocytopeni

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Plasma as a resuscitation fluid for volume-depleted shock: Potential benefits and risks

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

BACKGROUND: Cerebral venous sinus thrombosis (CVST) is a rare cerebrovascular disorder. The majority of these patients respond favorably to systemic anticoagulation. However, a subset of patients will deteriorate clinically, despite optimal medical therapy.

METHODS: Retrospective single center study of 28 consecutive CVST patients treated with systemic anticoagulation and additional endovascular therapy.

RESULTS: Median age was 37.5 years (range 15-76 years), there were 21 (75%) women, and 20 (71%) had thrombosis involving ≥2 venous sinuses. Intracranial hemorrhage (ICH) was present at admission in 18 patients (64%). Endovascular therapy consisted of local thrombolysis in 26 (93%) patients; 9 patients (32%) had additional mechanical thrombectomy, and in 2 (7%) patients thrombectomy alone was performed. Complete recanalization at end of the final intervention was achieved in 15 patients (54%), partial recanalization in 11 patients (39%), whereas there was no recanalization in 2 patients (7%). On follow-up imaging, conducted between 3 and 6 months, recanalization further improved to 76%, 19% and 5%, respectively. A favorable outcome (mRS ≤ 2) was achieved in 63% of patients at 3 months, which improved to 79% at 6 months. Post-procedural ICH or volume expansion of preexisting ICH was seen in 9 patients (32%). In total 5 patients died (18%).

CONCLUSIONS: Systemic anticoagulation with the addition of endovascular therapy with local thrombolysis and/or mechanical thrombectomy is a potential strategy to obtain recanalization in patients with CVST who deteriorate clinically despite medical therapy or are comatose. Endovascular therapy may increase the risk of ICH.

TidsskriftBritish Journal of Neurosurgery
Udgave nummer3
Sider (fra-til)259-265
Antal sider7
StatusUdgivet - jun. 2021

ID: 60405314